Stephanie van Hoppe

186 Appendices L I S T O F P UB L I C AT I ON S · Badr CE, Van Hoppe S , Dumbuya H, Tjon-Kon-Fat LA, Tannous BA. Targeting cancer cells with the natural compound obtusaquinone, J Natl Cancer Inst, 9 (2013) 643- 653. 10.1093/jnci/djt037 · van Hoppe S* , Durmus S*, Schinkel AH. The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice, Drug Resist Updat, (2016) 72-88. 10.1016/j. drup.2016.06.005 · Sparidans RW, van Hoppe S , Rood JJH, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandemmass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction, J Chromatogr B Analyt Technol Biomed Life Sci, (2016) 118-123. 10.1016/j.jchromb.2016.01.025 · Rood JJM, van Hoppe S , Schinkel AH, Schellens JHM, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol- metabolite in plasma and its application in mouse pharmacokinetic studies, J Pharm Biomed Anal, (2016) 123-131. 10.1016/j.jpba.2015.10.033 · van Hoppe S , Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation, Pharmacol Res, (2017) 43-50. 10.1016/j.phrs.2017.01.035 · van Hoppe S , Schinkel AH. What next? Preferably development of drugs that are no longer transported by the ABCB1 and ABCG2 efflux transporters, Pharmacol Res, (2017) 144. 10.1016/j.phrs.2017.05.015 · van Hoppe S* , Kort A*, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is LimitedbyP-Glycoprotein(P-GP/ABCB1)andBreastCancerResistanceProtein(BCRP/ ABCG2), Mol Pharm, 10 (2017) 3258-3268. 10.1021/acs.molpharmaceut.7b00257 * Contributed equally